Positron's Attrius Receives Health Canada Approval
FISHERS, Ind., Dec. 14, 2011 /PRNewswire/ -- Positron Corporation (OTCBB: POSC), a leading molecular imaging company specializing in the field of nuclear cardiology is pleased to announce today that on December 12, 2011, the Company's Positron Emission Tomography Scanner(s) Attrius & Attrius L have received approval for sale in Canada.
The Medical Device License from Health Canada was granted to the Attrius systems manufacturer, Neusoft Positron Medical Systems. NPMS is a joint venture between Neusoft Medical Systems of Shenyang, China and Positron Corporation. Positron Corporation has exclusive rights to sell Attrius in North America.
"We are pleased that our scanners are approved for the Health Canada system. It is great step forward for our technology and our integrated PET solutions," said Patrick G. Rooney, CEO of Positron. "The Canadian market is vast with a sophisticated approach to health care and is a market that requires the full cardiac PET solution. We have developed leading products and are integrating key segments critical to being able to offer the complete value chain. The Canadian market is very important to us and we intend to have a very strong presence throughout the country."
About Positron: Positron Corporation is a leading molecular imaging company providing innovative nuclear medicine technologies and services that are reshaping the field of nuclear cardiology. Through proprietary PET imaging systems and radiopharmaceutical solutions, Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes while practicing cost effective medicine. Positron has gained significant traction in a diverse industry and continues their strong commitment to excellence and advancing cardiac imaging solutions. More information about Positron is available at www.positron.com.